서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 75

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-01
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
DOI
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2009-03
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
DOI
2009-05
The Mandibular Advancement Device and Patient Selection in the Treatment of Obstructive Sleep Apnea

Lee, Chul Hee; Mo, Ji Hun; Choi, Ik Joon; Lee, Hyun Jong; Seo, Beom Seok; Kim, Dong Young; Yun, Pil Young; Yoon, In Young; Lee, Hye Won; Kim, Jeong Whun

Archives of Otolaryngology - Head and Neck Surgery, Vol.135 No.5, pp.439-444

DOI
2009-08
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma

Lee, J. O.; Lee, K. W.; Oh, D. Y.; Kim, J. H.; Im, S. A.; Kim, T. Y.; Bang, Y. J.

Annals of Oncology, Vol.20 No.8, pp.1402-1407

DOI
2010-08
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
view fileDOI
2011-01
High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
DOI
2012-01
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
DOI
2012-03
Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B
DOI
2012-05
The Effect of Positional Dependency on Outcomes of Treatment With a Mandibular Advancement Device

Lee, Chul Hee; Jung, Hahn Jin; Lee, Woo Hyun; Rhee, Chae Seo; Yoon, In Young; Yun, Pil Young; Kim, Jeong Whun

Archives of Otolaryngology - Head and Neck Surgery, Vol.138 No.5, pp.479-483

DOI
2012-07
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer
DOI
2012-08
The anatomical characteristics of three different endocardial lines in the left atrium: evaluation by computed tomography prior to mitral isthmus block attempt
DOI
2012-10
Treatment of ALK-Positive Non-Small Cell Lung Cancer

Bang, Yung-Jue

Archives of Pathology and Laboratory Medicine, Vol.136 No.10, pp.1201-1204

DOI
2013-01
RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: An evaluator-blind, randomized, pilot study

Lee, D. H.; Kang, S. M.; Feneran, A.; Youn, C. S.; Kim, J. K.; Cho, S.; Won, C. H.; Chang, S. E.; Lee, M. W.; Choi, J. H.; Moon, K. C.

Journal of the European Academy of Dermatology and Venereology, Vol.27 No.1, pp.e1-e7

DOI
2013-03
Nanoparticles in the treatment of angiogenesis-related blindness

Jo, Dong Hyun; Kim, Jin Hyoung; Lee, Tae Geol; Kim, Jeong Hun

Journal of Ocular Pharmacology and Therapeutics, Vol.29 No.2, pp.135-142

DOI
2013-09
Effects of porous beta-tricalcium phosphate-based ceramics used as an E-coli-derived rhBMP-2 carrier for bone regeneration

Lee, Jae Hyup; Ryu, Mi Young; Baek, Hae-Ri; Lee, Kyung Mee; Seo, Jun-Hyuk; Lee, Hyun-Kyung; Ryu, Hyun-Seung

Journal of Materials Science: Materials in Medicine, Vol.24 No.9, pp.2117-2127

DOI
2014-02
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
DOI
2014-05
Influencing factors on the effect of mandibular advancement device in obstructive sleep apnea patients: analysis on cephalometric and polysomnographic parameters
DOI
2014-08
Development of antirituximab antibodies in children with nephrotic syndrome

Ahn, Yo Han; Kang, Hee Gyung; Lee, Jiwon M.; Choi, Hyun Jin; Ha, Il-Soo; Cheong, Hae Il

Pediatric Nephrology, Vol.29 No.8, pp.1461-1464

DOI
2014-09
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2015-01
Topical TSG-6 administration protects the ocular surface in two mouse models of inflammation-related dry eye

Lee, Min Joung; Kim, Dong Hyun; Ryu, Jin Suk; Ko, Ah Young; Ko, Jung Hwa; Kim, Mee Kum; Wee, Won Ryang; Khwarg, Sang In; Oh, Joo Youn

Investigative Ophthalmology and Visual Science, Vol.56 No.9, pp.5175-5181

DOI
2015-04
만성질환 노인에서 임파워먼트 이론에 근거한 다학제적 자기관리 프로그램의 효과

박초롱; 송미순; 조비룡; 임재영; 송욱; 장희경; 박연환

Journal of Korean Academy of Nursing, Vol.45 No.2, pp.192-201

DOI
2015-05
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
DOI
2016-01
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
view fileDOI
2016-01
Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors
DOI
2016-02
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-A randomized phase III trial
DOI
2017
Prospective pilot study on combined use of pulsed dye laser and 1% topical rapamycin for treatment of nonfacial cutaneous capillary malformation

Doh, Eun Jin; Ohn, Jungyoon; Kim, Min Ji; Kim, Young Gull; Cho, Soyun

Journal of Dermatological Treatment, Vol.28 No.7, pp.672-677

DOI
2017-04
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
DOI
2017-09
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
DOI
2017-09
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
DOI
2018-01
Topical tacrolimus 0.03% for maintenance therapy in steroid-dependent, recurrent phlyctenular keratoconjunctivitis

Yoon, Chang Ho; Kim, Mee Kum; Oh, Joo Youn

Cornea, Vol.37 No.2, pp.168-171

DOI
2018-03
Long-term trastuzumab (Herceptin (R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
view fileDOI
2018-03
Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE
DOI
2018-06
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
DOI
2018-09
Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease

Mun, Yongseok; Kwon, Ji-Won; Oh, Joo Youn

BMC Ophthalmology, Vol.18 No.1, p. 237

DOI
2018-11
Symptom-alleviating effect and adverse effect of dienogest in Korean women with endometriosis

Jeong, Seon Hwa; Lee, Dayong; Kim, Seul Ki; Jee, Byung Chul

Gynecological Endocrinology, Vol.34 No.11, pp.970-974

DOI
2019-01
Long-Term Effects of In Vivo Genome Editing in the Mouse Retina Using Campylobacter jejuni Cas9 Expressed via Adeno-Associated Virus
DOI
2019-04
Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy
DOI
2019-07
Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent-3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial -
DOI
1 2